Lupus thrombocytopenia: pathogenesis and therapeutic implications
Open Access
- 1 January 2017
- journal article
- review article
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 28 (1) , 20-26
Abstract
Systemic Lupus Erythematosus (SLE) is frequently complicated by cytopenias. Thrombocytopenia is usually non-severe, and its frequency ranges from 20% to 40%. It is mostly an autoimmune process caused by autoantibodies against platelet surface glycoproteins and it is associated with worse prognosis in SLE. It can also be a result of SLE treatment with azathioprine, methotrexate and rarely hydroxychloroquine or thrombotic microangiopathy or macrophage activation syndrome. If thrombocytopenia is mild (>50x109/L) and there is no other evidence of disease, there is no need of therapy. Severe thrombocytopenia is less frequent and needs therapeutic management. Corticosteroids are the cornerstone of therapy. Continuous high dose oral prednisolone or pulse high dose methylprednisolone (MP) with or without intravenous immune globulin are used in the acute phase. Secondline agents (hydroxychloroquine, danazol, azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide, rituximab) are usually needed. Splenectomy is indicated for recurrent or resistant cases. There are no evidence-based guidelines to facilitate selection of one drug over another, but certainly the co-existence of other systemic SLE manifestations must be taken into account. Newer therapies are emerging, although there is no consensus on the treatment of refractory lupus thrombocytopenia due to the absence of controlled randomized trials.Keywords
This publication has 80 references indexed in Scilit:
- Two Cases of Refractory Thrombocytopenia in Systemic Lupus Erythematosus that Responded to Intravenous Low-Dose CyclophosphamideJournal of Korean Medical Science, 2013
- Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 yearsHaematologica, 2012
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals of the Rheumatic Diseases, 2012
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosusJournal of Clinical Investigation, 2009
- In vivo evidence for apoptosis in the bone marrow in systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2007
- Suspects in the tale of lupus-associated thrombocytopeniaClinical and Experimental Immunology, 2006
- Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolismRheumatology, 2005
- Thrombocytopenia in systemic lupus erythematosus: Association with antiplatelet and anticardiolipin antibodiesClinical Immunology and Immunopathology, 1990
- Evaluation of Azathioprine in Autoimmune Thrombocytopenia and Lupus ErythematosusScandinavian Journal of Haematology, 1973